MA53177A - Apyrases solubilisées, méthodes et utilisation - Google Patents

Apyrases solubilisées, méthodes et utilisation

Info

Publication number
MA53177A
MA53177A MA053177A MA53177A MA53177A MA 53177 A MA53177 A MA 53177A MA 053177 A MA053177 A MA 053177A MA 53177 A MA53177 A MA 53177A MA 53177 A MA53177 A MA 53177A
Authority
MA
Morocco
Prior art keywords
apyrases
solubilized
methods
solubilized apyrases
Prior art date
Application number
MA053177A
Other languages
English (en)
Inventor
Agostino Cirillo
Hilmar Ebersbach
Boerje Haraldsson
Thomas Huber
Guido Junge
Regina Link
Max Warncke
Chao Zou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA53177A publication Critical patent/MA53177A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
MA053177A 2018-07-18 2019-07-17 Apyrases solubilisées, méthodes et utilisation MA53177A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18184269 2018-07-18

Publications (1)

Publication Number Publication Date
MA53177A true MA53177A (fr) 2021-05-26

Family

ID=62985993

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053177A MA53177A (fr) 2018-07-18 2019-07-17 Apyrases solubilisées, méthodes et utilisation

Country Status (27)

Country Link
US (2) US12325870B2 (fr)
EP (1) EP3824079A1 (fr)
JP (2) JP7425784B2 (fr)
KR (1) KR102919646B1 (fr)
CN (6) CN119020318A (fr)
AR (1) AR115790A1 (fr)
AU (1) AU2019306821B2 (fr)
BR (1) BR112021000586A2 (fr)
CA (1) CA3103684A1 (fr)
CL (1) CL2021000129A1 (fr)
CO (1) CO2021000210A2 (fr)
CR (1) CR20210021A (fr)
CU (1) CU24746B1 (fr)
EA (1) EA202190057A1 (fr)
EC (1) ECSP21002804A (fr)
IL (1) IL280191A (fr)
JO (1) JOP20210008A1 (fr)
MA (1) MA53177A (fr)
MX (1) MX2021000542A (fr)
MY (1) MY203583A (fr)
PE (1) PE20210185A1 (fr)
PH (1) PH12021550122A1 (fr)
SG (1) SG11202011776RA (fr)
TW (1) TWI857965B (fr)
UY (1) UY38299A (fr)
WO (1) WO2020016804A1 (fr)
ZA (1) ZA202007187B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
WO2021243173A1 (fr) * 2020-05-28 2021-12-02 Charm Sciences, Inc. Procédés et ensembles pour analyse d'échantillon
KR20250044705A (ko) 2022-07-29 2025-04-01 노파르티스 아게 Cd39, 재조합 cd39를 사용하는 급성 기관 손상의 치료
IL318397A (en) 2022-07-29 2025-03-01 Novartis Ag Improved production of CD39 variants
AU2024360371A1 (en) * 2023-10-13 2026-02-26 Danisco Usa Inc. Methods and compositions for aging and mitochondrial health

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
AU772460B2 (en) 1998-10-16 2004-04-29 Immunex Corporation Inhibitors of platelet activation and recruitment
US20020002277A1 (en) * 1998-10-16 2002-01-03 Maliszewski Charles Richard Inhibitors of platelet activation and recruitment
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
CA2578908C (fr) 2005-03-17 2020-05-26 National Research Council Of Canada Vecteurs d'expression pour l'expression genetique transitoire et cellules mammaliennes les exprimant
WO2008002157A1 (fr) 2006-06-27 2008-01-03 Agresearch Limited Apyrases et utilisations correspondantes
WO2011088231A1 (fr) 2010-01-13 2011-07-21 Apt Therapeutics, Inc. Traitement thérapeutique à l'apyrase des états pathologiques hémorragiques
US8771683B2 (en) * 2010-01-13 2014-07-08 Apt Therapeutics, Inc. Therapeutic apyrase constructs, apyrase agents, and production methods
EP3604331A1 (fr) 2013-12-20 2020-02-05 Novartis AG Nouvelles cellules eucaryotes et procédés d expression de manière recombinante d'un produit d'intérêt
AU2014369177B2 (en) 2013-12-20 2017-04-20 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
UY38299A (es) * 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos

Also Published As

Publication number Publication date
MY203583A (en) 2024-07-05
JP7425784B2 (ja) 2024-01-31
CR20210021A (es) 2021-03-23
PE20210185A1 (es) 2021-02-02
CN112424346A (zh) 2021-02-26
AU2019306821A1 (en) 2020-12-24
SG11202011776RA (en) 2021-02-25
CA3103684A1 (fr) 2020-01-23
CN119020320A (zh) 2024-11-26
AU2019306821B2 (en) 2022-09-29
EP3824079A1 (fr) 2021-05-26
MX2021000542A (es) 2021-03-29
JOP20210008A1 (ar) 2021-01-12
ECSP21002804A (es) 2021-04-29
AR115790A1 (es) 2021-02-24
CN112424346B (zh) 2024-08-06
CL2021000129A1 (es) 2021-08-20
CO2021000210A2 (es) 2021-01-18
US12325870B2 (en) 2025-06-10
WO2020016804A1 (fr) 2020-01-23
US20220356455A1 (en) 2022-11-10
TWI857965B (zh) 2024-10-11
US20250179447A1 (en) 2025-06-05
UY38299A (es) 2020-02-28
IL280191A (en) 2021-03-01
CN119162148A (zh) 2024-12-20
KR20210035806A (ko) 2021-04-01
PH12021550122A1 (en) 2021-09-27
ZA202007187B (en) 2022-06-29
BR112021000586A2 (pt) 2021-04-06
JP2024023297A (ja) 2024-02-21
CU20210008A7 (es) 2021-08-06
CU24746B1 (es) 2025-04-04
TW202016299A (zh) 2020-05-01
EA202190057A1 (ru) 2021-08-24
CN119020319A (zh) 2024-11-26
KR102919646B1 (ko) 2026-01-29
JP2021529550A (ja) 2021-11-04
CN119020321A (zh) 2024-11-26
CN119020318A (zh) 2024-11-26

Similar Documents

Publication Publication Date Title
IL293061A (en) Collaborative networking systems, methods, and devices
IL272089A (en) Compounds, compositions and methods
EP3687093A4 (fr) Procédé, appareil, et dispositif de communication
EP3780786A4 (fr) Procédé et appareil de communication
EP3843739A4 (fr) Nouvelles méthodes
EP3672991A4 (fr) Molécules anti-cd137 et utilisation correspondante
EP3843738A4 (fr) Nouvelles méthodes
EP3637683C0 (fr) Procédés, fonction d'entité et système de gestion de session
EP3713364A4 (fr) Procédé et appareil de communication
EP3801527A4 (fr) Nouvelles méthodes
EP3633034A4 (fr) PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE
EP3611994A4 (fr) Procédé de planification semi-persistante, équipement utilisateur et dispositif de réseau
IL282178A (en) Products, uses & methods
EP3817422A4 (fr) Procédé et dispositif de communication
EP3771283A4 (fr) Procédé et appareil de communication
EP3886504C0 (fr) Procédé de communication d'informations, équipement utilisateur et dispositif de réseau
EP3582169A4 (fr) Appareil, système et procédé de présentation de marchandises
KR102528125B9 (ko) 정보 처리 방법, 장치 및 기기
EP3863334A4 (fr) Procédé et appareil de communication
EP4059305A4 (fr) Procédés et appareils de communication
EP3709751A4 (fr) Procédé d'accès aléatoire, équipement utilisateur et dispositif de réseau
MA53177A (fr) Apyrases solubilisées, méthodes et utilisation
EP3720219A4 (fr) Procédé et dispositif de communication
EP3566166A4 (fr) Gestion de vulnérabilités de sécurité
EP3655001A4 (fr) Méthodes d'aphérèse et utilisations associées